Skip to main content

Research Repository

Advanced Search

Professor David Allsup's Recognition (58)

Member of the British Society for Haematology General Haematology Task Force
2024 - 2027

Educational Supervisor
2004 - 2030

Description Educational supervisor to multiple speciality trainees, internal medcine trainees and foundation doctors.
Affiliated Organisations Hull University Teaching Hospitals NHS Trust

Regional lead for intrathecal chemotherapy
2014 - 2024

Description Regional lead for intrathecal chemotherapy
Affiliated Organisations Hull University Teaching Hospitals NHS Trust

Local lead for delivery of 100,000 genome project
2016 - 2020

Description Local lead for the delivery of 100,000 genome project in Hull and East Yorkshire.
I oversaw recruitement of around 300 persons to this programmme
Affiliated Organisations Hull University Teaching Hospitals NHS Trust

Medical advsior to NICE
2024 - 2024

Description Medical advisor to NHS and NICE in relation to assessment of medical technologies for haemophilia treatment
Affiliated Organisations Hull University Teaching Hospitals NHS Trust

Chair of Regional Haemostasis Multidisciplinary team
2004 - 2030

Description Chair of the regional haemostasis multidisciplinary team.
Affiliated Organisations Hull University Teaching Hospitals NHS Trust

Member of haemato-oncology multidisciplinary team
2004 - 2030

Description Member of regional haemato-oncology MDT.
Chair of committee 2015-2023
Affiliated Organisations Hull University Teaching Hospitals NHS Trust

Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia
2024 - 2024

Description Management of acute leukaemia and pregnancy outcomes in patients with current or previous leukaemia

Dr Lukas Pitel, Dr Matthew Northgraves, Prof. Judith Cohen, Dr Chao Huang, Mr. John Turgoose, Dr Sahra Ali, Prof. Mhairi Copland, Panagiotis D. Kottaridis, Dr David Allsup

ePoster presentation at British Society for Haematology Meeting Liverpool, April 2024.
Projects LIPS: A prospective registry-based cohort study to monitor the diagnosis and management of acute leukaemia in pregnancy
Org Units Centre for Biomedicine
URL https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.19399

A single centre assessment of the frequency and clinical relevance of discrepant factor VIII assays both in persons without a disorder of haemostasis and in those with haemophilia A
2024 - 2024

Description Lead author on poster presentation at European Society for Haemophilia and Allied Disorders Meeting, Frankfurt, February 2024.
Affiliated Organisations Hull York Medical School

Interim Analysis of Real-World Effectiveness and Usage of Recombinant Factor IX Fc for Surgical Haemostasis from the 24-Month Prospective, Non-Interventional B-MORE Study
2024 - 2024

Description Coauthor on poster presentation at European Association for Haemophilia and Allied Disorders Meeting Frankfurt February 2024.
Affiliated Organisations Hull York Medical School

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact
2023 - 2023

Description Co-author on the above conference presentation ,poster, at the American Society of Haematology meeting, San Diego, USA, December 2023.
Affiliated Organisations University of Hull

Targeted Agents in CLL: Advancements in Overall Survival Outcomes?
2023 - 2023

Description Co-author on the above poster presentation at the American Society of Haematology Meeting, San Diego USA, December 2023.
Affiliated Organisations University of Hull

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients in FLAIR Study with previously untreated chronic lymphocytic leukaemia: Assessment of mutational landscape of patients at baseline and prognostic impact
2023 - 2023

Description Co-author on above poster presentation at the American Society of Haematology Meeting San Diego USA, December 2023.
Affiliated Organisations University of Hull

Using peripheral blood (PB) measurable residual disease (MRD) levels to predict <0.01% bone marrow disease (BM uMRD4): identification of effective PB targets for CLL treatment cessation in the ibrutinib+venetoclax arm of the FLAIR trial
2023 - 2023

Description Co-author on the above presentation at the American Society of Haematology meeting, San Diego, USA, December 2023.
Affiliated Organisations University of Hull

Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: Report of the Phase III UK NCRI FLAIR study
2023 - 2023

Description Co-author on the above oral presentation at the Amercian Society Haematology, San Diego, December 2023.
Affiliated Organisations University of Hull

Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment.
2023 - 2023

Description Co-author on the above oral presentation at the International Workshop for CLL, Boston, USA.
Affiliated Organisations University of Hull

Does the Life Expectancy of Elderly CLL patients receiving upfront Targeted Agents approach the Life Expectancy of the General Population?
2023 - 2023

Description Oral presentation at the International Workshop in CLL, Boston, USA.
Affiliated Organisations University of Hull
Research Centres/Groups Aura Innovation Centre

United Kingdom Chronic Lymphocytic Leukaemia Forum
2010 - 2025

Affiliated Organisations Hull York Medical School